The era of disease modifying therapy for Multiple Sclerosis (MS), which began with ACTH in the 1950s, has truly accelerated in the past 2 decades. Neuro-ophthalmologists should be aware of the important recent therapeutic advances that will impact their patients with MS.
Date
2019-03
Language
eng
Format
video/mp4
Relation is Part of
NANOS Annual Meeting 2019: New Information I Should Know
Publisher
Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
